The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies.

Immune checkpoint inhibitors and adoptive tumor-infiltrating lymphocyte (TIL) therapies have profoundly improved the survival of melanoma patients. However, a majority of patients do not respond to these agents, and many responders experience disease relapse. While numerous innovative treatments are...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Cancer Ther
Prif Awduron: Varghese, Sruthy, Pramanik, Snigdha, Williams, Leila J., Hodges, Hannah R., Hudgens, Courtney W., Fischer, Grant M., Luo, Catherine K., Knighton, Barbara, Tan, Lin, Lorenzi, Philip L., Mackinnon, Andrew L., McQuade, Jennifer L., Hailemichael, Yared, Roszik, Jason, Peng, Weiyi, Vashisht Gopal, Y. N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7933078/
https://ncbi.nlm.nih.gov/pubmed/33361272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0430
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg